睾酮给药对女变男变性者血清和尿激肽释放酶浓度的影响。

Effect of testosterone administration on serum and urine kallikrein concentrations in female-to-male transsexuals.

作者信息

Slagter Margrita H, Scorilas Andreas, Gooren Louis J G, de Ronde Willem, Soosaipillai Antoninus, Giltay Erik J, Paliouras Miltiadis, Diamandis Eleftherios P

机构信息

Department of Endocrinology, Vrije Universiteit University Medical Centre, Amsterdam, The Netherlands, and Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada.

出版信息

Clin Chem. 2006 Aug;52(8):1546-51. doi: 10.1373/clinchem.2006.067041. Epub 2006 Jun 15.

DOI:10.1373/clinchem.2006.067041

PMID:16777918

Abstract

BACKGROUND

Concentrations of human tissue kallikreins (hKs), a group of 15 secreted serine proteases found in many tissues, are modulated by steroid hormones in cancer cell lines. To gain insight into in vivo kallikrein regulation we measured kallikrein concentrations in serum and urinary tissue in female-to-male transsexuals before and after testosterone administration.

METHODS

We collected blood and urine samples before treatment and after 4 and 12 months from 28 female-to-male transsexuals who received 250 mg of testosterone esters intramuscularly every 2 weeks. We used ELISA assays to measure multiple kallikreins in serum and urine.

RESULTS

After testosterone administration, serum testosterone concentrations increased by approximately 15-fold. Serum kallikrein concentrations increased dramatically for hK3 (prostate-specific antigen) and increased moderately for hK2, hK5, hK6, hK7, hK8, hK10, and hK11. In urine, we noted major increases for hK3 and hK2 only. For all other kallikrein concentrations, we observed no considerable changes.

CONCLUSIONS

We conclude that, in serum and urine of female-to-male transsexuals after testosterone administration, hK3 (prostate-specific antigen) and to a lesser extent hK2 concentrations increase dramatically, but concentration of other kallikreins increase either moderately in serum (hK5, hK6, hK7, hK8, hK10, and hK11) or not at all in either serum (hK4, hK13, hK14) or urine (hK4, hK5, hK6, hK7, hK8, hK10, hK11, hK13, hK14).

摘要

背景

人类组织激肽释放酶（hKs）是一组在许多组织中发现的15种分泌型丝氨酸蛋白酶，其浓度在癌细胞系中受类固醇激素调节。为深入了解体内激肽释放酶的调节机制，我们测量了女性变男性的变性者在睾酮给药前后血清和尿组织中的激肽释放酶浓度。

方法

我们收集了28名每2周接受250mg睾酮酯肌肉注射的女性变男性变性者在治疗前、治疗后4个月和12个月的血液和尿液样本。我们使用酶联免疫吸附测定法（ELISA）测量血清和尿液中的多种激肽释放酶。

结果

睾酮给药后，血清睾酮浓度增加了约15倍。血清中hK3（前列腺特异性抗原）的激肽释放酶浓度显著增加，hK2、hK5、hK6、hK7、hK8、hK10和hK11的浓度适度增加。在尿液中，我们仅注意到hK3和hK2有显著增加。对于所有其他激肽释放酶浓度，我们未观察到明显变化。

结论

我们得出结论，在女性变男性的变性者睾酮给药后的血清和尿液中，hK3（前列腺特异性抗原）浓度显著增加，hK2浓度在较小程度上显著增加，但其他激肽释放酶的浓度在血清中（hK5、hK6、hK7、hK8、hK10和hK11）适度增加，或在血清（hK4、hK13、hK14）或尿液（hK4、hK5、hK6、hK7、hK8、hK10、hK11、hK13、hK14）中根本没有增加。